Skip to main content
Premium Trial:

Request an Annual Quote

SeqLL, FBI Partner to Develop Sequencing-Based Forensic Technology

NEW YORK — Sequencing instrument and services firm SeqLL said on Tuesday that it has signed a Cooperative Research and Development Agreement (CRADA) with the US Federal Bureau of Investigation to determine the forensic capabilities of SeqLL's RNA sequencing technology.

Under the terms of the two-year CRADA, the FBI's laboratory division and SeqLL will work together to develop an assay for forensic body fluid identification using the company's True Single Molecule Sequencing platform.

Financial and other terms of the arrangement were not disclosed.

"We appreciate the opportunity this CRADA provides, to methodically develop forensic applications utilizing SeqLL's technology," SeqLL Founder and CEO Daniel Jones said in a statement. "We look forward to demonstrating how single-molecule, PCR-free approaches are ideally suited for this space."

The Scan

Cystatin C Plays Role in Immunosuppression, Cancer Immunotherapy Failure, Study Finds

A study in Cell Genomics provides insight into how glucocorticoids can lead to cancer immunotherapy failure via cystatin C production.

Aging, Species Lifespan Gene Expression Signatures Overlap

An Osaka Metropolitan University team reports in Nucleic Acids Research that transcriptional signatures of aging and maximum lifespan have similarities.

Splicing Subgroup Provides Protocols for Evaluating Splicing Variant Data

The group presents their approach on how to apply evidence codes to splicing predictions and other data in the American Journal of Human Genetics.

Single-Cell Transcriptomic Atlas of Mouse Cochlea to Aid Treatment Development

Researchers in PNAS conducted single-cell and single-nuclear sequencing of about 120,000 cells at three key timepoints in cochlear development to generate a transcriptomic atlas.